Synthesis method of clofarabine of nucleoside analogues

A compound, hydrobromic acid technology, applied in the directions of drug combination, sugar derivatives, organic chemistry, etc., can solve the problems of complicated operation steps, expensive reagents, etc., and achieve the effects of high yield, easy operation and mild conditions

Inactive Publication Date: 2009-10-14
杭州容立医药科技有限公司
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] The advantage of route two over route one is that two steps are combined into one step, but the reagents used are relatively expensive and the operation steps are still relatively complicated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of clofarabine of nucleoside analogues
  • Synthesis method of clofarabine of nucleoside analogues
  • Synthesis method of clofarabine of nucleoside analogues

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Preparation of compound (3): synthesis of 1,3,5-tris-oxy-benzoyl ribose (3)

[0044] Add 500mL of dichloromethane and 9.7mL of methanol to a 1L reaction flask, cool to 0~5℃ in an ice-water bath, carefully add 17.8mL of acetyl bromide while stirring, stir for 10 minutes at 0℃, add 100.9g (1), keep the temperature React at 0℃~5℃ for about 2 hours. After the reaction is complete, add 200 mL of water, stir at room temperature for 1 hour, separate the organic layer, extract the aqueous layer with dichloromethane (2×200 mL), combine the organic layers, and dry with magnesium sulfate About half an hour, filter, concentrate to about 300mL, cool to 0°C in an ice-water bath, add 600mL n-heptane while stirring, a white solid precipitates, continue stirring at 0°C for 2 hours, filter, the crystals are 3×50mL n-heptane / two Wash with methyl chloride (2 / 1), immediately transfer the crystals to a beaker, and put them in a vacuum desiccator to drain. 42 g of white powder (2) was obtained, w...

Embodiment 2

[0046] Preparation of compound (4): Synthesis of 2-deoxy-2-fluoro-1,3,5-tri-oxy-benzoyl-α-D-ribofuranose (4)

[0047] Add 13.9g (2) and 200mL dichloromethane into a 500mL reaction flask, add 14.5g DAST under stirring, heat to 40~42℃ and stir for about 18 hours, cool to room temperature, add saturated NaHCO 3 200mL of the solution, stirred for about 30 minutes, transferred to a separatory funnel, separated the organic phase, and then washed the organic phase with water (2×200mL), dried with magnesium sulfate for about half an hour, filtered, evaporated the solvent under reduced pressure, and the residue was diluted to 100ml Recrystallize from absolute ethanol. 9.2 g of white powder (4) was obtained, with a yield of 66%. 32g of compound (3) (195mmol) was added to 350ml of DMF (anhydrous treatment), 28g of sodium hydride was added under ice-water bath, stirred for half an hour, 97ml of 2,4-dichlorobenzyl chloride was added dropwise, and the reaction was carried out at 35°C. After 4 h...

Embodiment 3

[0049] Preparation of compound (5): Synthesis of 1-bromo-2-deoxy-2-fluoro-3,5-di-oxy-benzoyl-α-D-ribofuranose (5)

[0050] Add 13.8g (4) and 70mL dichloromethane to a 250mL reaction flask, add 17.5mL hydrogen bromide acetic acid solution (33%) under stirring at room temperature, stir at room temperature for about 18 hours, and then water (2×200mL), saturated NaHCO 3 The organic phase was washed with 200 mL of the solution, dried with magnesium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain 12.4 g of oil (4) with a yield of 99%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel synthesis method of clofarabine , that is 6-amino-2-Cl-9-(2-deoxidation-2-Fl-Beta-D-ribofuranose)-9H-purine for treating leukemia, which comprises the following steps of crystallization, fluoridation, bromination reaction, ammonia reaction, selection reaction and methanol reaction. The invention has simple synthesis procedure, mild condition, easy operation, low cost, high yield and easy amplification, and adapts to the industrial production.

Description

Technical field [0001] The present invention relates to the new synthesis of clofarabine, a drug for treating leukemia, namely 6-amino-2-chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)-9H-purine method. technical background [0002] 6-Amino-2-chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)-9H-purine is a nucleotide analog, approved abroad for the treatment of refractory or relapsed children Acute lymphocytic leukemia. The drug currently has the following two synthetic methods: [0003] 1): Using 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose (2) and 2,6-dichloropurine (6) as starting materials. [0004] The route is shown in the following reaction equation: [0005] [0006] The reagents used in the above-mentioned whole route are relatively cheap, but the disadvantages are that the steps are long, the yield is low, and the operation is relatively cumbersome, which is not suitable for large-scale production. [0007] 2) Also use 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose (2) and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07H19/173A61P35/02
Inventor 李航何党军杨永民金远锋任建强
Owner 杭州容立医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap